Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
Therapeutic candidate IVA337 is a next generation PanPPAR agonist addressing all the relevant clinical and regulatory features of NASH NATIVE clinical study plans to enroll 225 patients in 12 European countries Headline results are expected mid-2018 DAIX, …